Penumbra Inc Stock Price, News & Analysis

Penumbra, Inc. (NYSE: PEN) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022. The management team will present at 11:15 AM ET (8:15 AM PT). Interested investors can access an audio webcast of the presentation through the company's website, available for at least two weeks post-event. Penumbra is dedicated to innovative healthcare solutions, serving providers in over 100 countries.

Penumbra, Inc. (NYSE: PEN) announced positive results from the CHEETAH clinical study of its CAT RX Catheter at the TCT conference. The study achieved high rates of blood clot removal and restored blood flow in patients with high thrombus burden. Key findings included a 99.5% reduction in TIMI thrombus grade and 97.5% of patients achieving TIMI flow grade 3 post-treatment. No serious device-related adverse events were reported. The study emphasizes the effectiveness and safety of continuous powered aspiration thrombectomy in acute coronary syndrome interventions.

Penumbra, Inc. (NYSE: PEN) reported strong financial results for Q3 2021, with a revenue increase of 25.8% year-over-year, reaching $190.1 million. Vascular product sales surged 40.3% to $105.5 million, while neuro products rose 11.5% to $84.7 million. Gross profit improved to 63.1% of total revenue, totaling $119.9 million. Operating income shifted to $8.8 million from a loss of $20.2 million a year earlier. The company also raised its 2021 revenue guidance to between $735 million to $740 million, reflecting a growth of 31% to 32% over 2020.

Penumbra, Inc. (NYSE: PEN) will host a conference call on November 3, 2021, at 4:30 PM ET to discuss its third quarter 2021 financial results. A press release will be issued post-market closure on the same day. Investors can access the call via phone or webcast on the company's website. Penumbra, based in Alameda, California, specializes in innovative therapies addressing significant medical conditions across over 100 countries.

Penumbra, Inc. (NYSE: PEN) will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 11:00 AM EDT / 8:00 AM PDT. A webcast of the presentation can be accessed via the company’s investor section on their website and will remain available for two weeks post-event. Penumbra, based in Alameda, California, specializes in innovative healthcare therapies, providing solutions to medical conditions across over 100 countries.

Penumbra, Inc. (NYSE: PEN) reported a strong second quarter for 2021, with revenues reaching $184.3 million, marking a 75.3% increase year-over-year. Vascular product sales surged 117.6% to $100.7 million, while neuro product sales grew 42% to $83.6 million. Gross profit stood at 64.4% of total revenue. Operating income improved to $10.3 million from a loss of $17.6 million in Q2 2020. The company also raised its full-year revenue guidance to $720 million to $730 million, reflecting a projected 28% to 30% growth over 2020.

Penumbra, Inc. (NYSE: PEN) will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 11:00am ET / 8:00am PT. The event will showcase the company's innovative healthcare therapies aimed at addressing significant medical needs. Interested parties can access a webcast of the presentation via the investors' section of Penumbra's website, available for two weeks post-event. Penumbra operates primarily in the US, Europe, Canada, and Australia, focusing on cutting-edge products in the healthcare sector.

Penumbra, Inc. (NYSE: PEN) has scheduled a conference call to discuss its second quarter 2021 financial results on August 9, 2021, at 4:30 PM ET. A press release with detailed financial results will be issued after the market closes on the same day. Interested parties can access the call by dialing (833) 350-1434 or through a webcast available on the company's website. Penumbra is focused on developing innovative therapies to address significant medical needs globally.

Penumbra, Inc. (NYSE: PEN) announces FDA 510(k) clearance and commercial availability of the RED^™ 62 Reperfusion Catheter, enhancing treatment capabilities for acute ischemic stroke patients. Designed for complex distal vessel anatomy, RED 62 provides powerful aspiration to effectively remove blood clots. Medical professionals praised its responsiveness and effectiveness. This launch expands the Penumbra System^® portfolio and aims to reduce healthcare costs while improving patient outcomes.